Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Antengene Presents Results from Three Investigational Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Nov. 6, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-11-06 09:08 1373

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

2024-11-06 08:30 1340

MedAdvisor Solutions Launches Telehealth Service on MedAdvisor Patient App, Further Enhancing Access to Care

Patients can now book virtual provider consultations within the App MELBOURNE, Australia, Nov. 6, 2024 /PRNewswire/ -- MedAdvisor Solutions, a global leader in pharmacy-driven patient engagement solutions, announced today that new Telehealth functionality is now available within the MedAdvisor ...

2024-11-06 06:47 1367

Embrace Autumn Outdoor Activities: Renowned Traditional Chinese Medicine Expert Professor Tinly Wong Tin-Chee Offers Effective Solutions for Relieving Post-Exercise Muscle Soreness with Massage, Herbal Oils, and Plasters

HONG KONG, Nov. 4, 2024 /PRNewswire/ -- As autumn settles in and temperatures begin to drop, many individuals embrace outdoor activities such as running, cycling, and hiking, delighting in the beauty of nature. However, post-exercise muscle soreness can become a common challenge for those who typ...

2024-11-04 09:00 2841

Embrace Autumn Outdoor Activities: Renowned Traditional Chinese Medicine Expert Professor Tinly Wong Tin-Chee Offers Effective Solutions for Relieving Post-Exercise Muscle Soreness with Massage, Herbal Oils, and Plasters

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

MELBOURNE, Australia, Nov. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement bythe United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals[1] ...

2024-11-04 06:07 1500

The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024

WASHINGTON, Nov. 1, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve Pl...

2024-11-01 21:00 1676

DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology

* Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation * Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- OnOctober 30, a Ko...

2024-11-01 21:00 3391

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

* This approval marks the second international marketing authorization for sugemalimab outside ofChina, following its recent approval by the European Commission. * The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination...

2024-10-31 13:00 1716

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...

2024-10-31 12:34 1532

Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients

ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains th...

2024-10-31 12:00 1633

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-10-30 22:24 1901

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...

2024-10-29 20:30 2128

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the ...

2024-10-29 19:27 2135

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

Discovery of cancer risk associations for six novel genes

REYKJAVIK, Iceland, Oct. 29, 2024 /PRNewswire/ --Scientists at deCODE genetics/Amgen, and their collaborators have discovered six novel genes with rare germline variants that associate with cancer risk. The findings are published today in Nature Genetics under the title "Gene-based burden tests o...

2024-10-29 18:00 1344

Discovery of cancer risk associations for six novel genes

RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China

YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially...

2024-10-29 12:00 1332

The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

PARIS, Oct. 29, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the Integratio...

2024-10-29 11:01 1396

The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics

SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-10-29 07:57 1495

Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY

-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while d...

2024-10-29 06:32 1373

Lilly's Mounjaro® (tirzepatide) Approved in Hong Kong in KwikPen® Presentation for Chronic Weight Management and Type 2 Diabetes, Offering a New Option for the Treatment of Obesity, Overweight and Type 2 Diabetes

* Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 * Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials6-12 * Mounjaro represents a new class of obesity and diabetes medicines and is expected to be ava...

2024-10-28 15:12 1396

/C O R R E C T I O N -- Seegene Inc./

In the news release, Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative, issued 24-Oct-2024 by Seegene Inc. over PR Newswire, we are advised by the company that the second photo and its caption should be removed as origina...

2024-10-28 12:50 3666

123 4 5 ... 187

Week's Top Stories

DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam

[Picked up by 279 media titles]

2024-11-08 20:11

$DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam$